Cowboys' Jerry Jones reveals 2010 cancer diagnosis, overcame stage 4 melanoma
Jones made a passing reference in the documentary to undergoing cancer treatments 'about a dozen years ago.' Jones confirmed to the Dallas Morning News that he was diagnosed with stage 4 melanoma in June of 2010 and underwent treatment over the following decade.
Advertisement
Jones said he received 'fabulous' treatment at MD Anderson Cancer Center in Houston and overcame the cancer thanks to an experimental drug called PD-1, or Programmed Cell Death Protein 1, per the Dallas Morning News.
A stage 4 cancer diagnosis means melanoma has spread to other places throughout the body, such as the brain, lungs, liver or gastrointestinal (GI) tract, and it may have spread to distant points in the skin, per the Melanoma Research Alliance.
According to the National Library of Medicine, research showed that PD-1 'acted as a 'brake' role in immune function, and suggested that immune checkpoint inhibition may reactivate T cells and eliminate cancer cells more effectively.' T cells are part of the immune system and help protect the body from infection.
Jones said he had two lung surgeries and two lymph node surgeries in the decade after his cancer diagnosis. He confirmed to the Dallas Morning News that he is tumor-free.
Jones, 82, has held the title of Cowboys owner and general manager since he bought the franchise in 1989. After winning three Super Bowls in four years during the mid-90s with coach Jimmy Johnson, the team has struggled to find postseason success since. Dallas is in a 29-year championship drought and is the only NFC team to fail to reach a conference championship game over that span.
The Cowboys have compiled a 319-261 record under Jones. Their last playoff appearance came in 2023, when they lost to the Green Bay Packers in the wild-card round.
Spot the pattern. Connect the terms
Find the hidden link between sports terms
Play today's puzzle
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Cowboys Training Camp: Takeaways from Practice 14, Oxnard is Over, update on Diggs injury
The Dallas Cowboys have concluded their final West Coast practice of the 2025 calendar, and they are set to pack up and return to Texas in advance of their second preseason game. The Baltimore Ravens will meet them in Arlington for a Saturday night matchup, but aside from a walkthrough and some media availability on Thursday, it's a wrap on yet another four-week stint on Oxnard, CA. Wednesday's practice was highlighted by a sensational interception by a defensive lineman, giving some hints as far as what can be expected once the games count, as the Cowboys' new coaching staff continues to commit to the hide-and-no-seek mantra when it comes to what they'll reveal during the exhibition season. Here are the biggest takeaways from the final training camp practice of 2025. Sam Williams' Pick-6 Late in practice, working on goal-line situations, Dak Prescott was intercepted by defensive end Sam Williams. Williams returned the interception the entire length of the field for a Practice Pick-6. That's Dante Fowler (13) lined up wide of right tackle Terence Steele. Rookie DE Donovan Ezeiruaku (41) is standing up in the C gap and DT Solomon Thomas in the A gap. On the OL's left side, that's Mazi Smith (58) and Marshawn Kneeland (94) taking on the LG and LT, with Kenneth Murray (59) and finally Williams (54). Running Back Depth Chart According to Dallas News' Calvin Watkins, the running back pecking order seems to be settling in. Vaughn got first-team reps again. But as camp is on the cusp of closing, it seems Javonte Williams has the lead as the Week 1 starter at running back. The backup is between Hunter Luepke, Jaydon Blue and Miles Sanders. Injury Updates LT Tyler Guyton (broken knee) began working on the resistance cords on Wednesday, per ESPN's Todd Archer RB Miles Sanders (knee) returned to team drills DE Payton Turner (ribs) returned to practice RB Jaydon Blue still isn't practicing with his knee/ankle issue Trevon Diggs has ramped up to daily sessions with trainer Britt Brown, also doing ball drills Steal of the draft? The Cowboys double-dipped at running back in the spring, taking two on Day 3 in fifth-round pick Jaydon Blue and seventh-round pick Phil Mafah. Mickey Spagnola had an interesting tidbit on Wednesday that may help explain how a battering ram like Mafah fell that far despite having back-to-back 1,000-yard seasons at Clemson. In an extremely deep running back class, Mafah played his final year in college with a torn labrum, and wasn't able to work out for teams in the pre-draft process. There's an assumption the Cowboys are going to carry both veteran RBs they signed this summer, but that may not be the case. MIcah Check Still no update on renewed contract talks between Jerry Jones and Micah Parsons, both who brushed off questions about progress or trade talk. This article originally appeared on Cowboys Wire: Cowboys Training Camp: Takeaways from Practice 14, Oxnard is Over
Yahoo
20 minutes ago
- Yahoo
Royals Rumblings – News for August 14, 2025
While they still won the series, the Royals felt they let the sweep get away from them: 'Every game is critical, obviously,' Royals outfielder Kyle Isbel said. 'We are at that time of the year. We are hoping to get hot and win a lot of games. It's a big homestand coming up and we just gotta keep rolling.' The Royals fell short in an 8-7 loss to the Nationals on Wednesday, sliding another half-game behind the Yankees in the wild-card chase. For KC (60-61), the deficit could grow further, as the Yankees faced the Minnesota Twins on Wednesday night. 'We had a really nice opportunity today to come out and start this homestand with a sweep …' Royals first baseman Vinnie Pasquantino said. 'At the end of the day, we won the series. So that's a net positive. Just stings a little bit when the game goes like that to finish out the series.' With Michael Lorenzen returning from injury, the Royals are reshuffling their pitching staff: 'Just trying to put the best rotation out there right now and also give us the best chance to match up out of the 'pen and give us a little depth,' Quatraro said of Falter's transition to the bullpen. Bergert and Falter were two of the pitchers the Royals acquired at the Trade Deadline, with Bergert (and righty Stephen Kolek, who is in Triple-A) coming from the Padres and Falter from the Pirates. Both immediately slotted into the Royals' rotation because of the three starters on the injured list at the time in Lorenzen, Cole Ragans and Kris Bubic. Kevin O'Brien at the Royals Reporter looks at Kansas City's baserunning woes struggles this season compared to last: The most significant difference from this season's squad is Maikel, who created 7.6 total baserunning runs last year. That is an 8.3-run difference from 2025, which demonstrates how far Garcia has slid on the basepaths, a primary strength of his in 2024. The Venezuelan infielder was not just good at gaining extra bases on hits (2.6 run value), but he was sensational on stolen bases. His 5.1 stolen base run value was not only the best mark on the team, but it was 1.4 runs better than Dairon Blanco, who had the second-best mark, and 4.5 runs better than Witt, who had the third-best mark. Salvador Perez and other catchers dished on the physical grind of the position: To Langeliers, for example, the worst place to be hit is the top of the knee, just above the edge of the shin guard. Hearing his fellow catcher's testimony, Perez rolled up his right pant leg to reveal a large, dark bruise in the middle of a tattoo on his thigh. 'I got one,' Perez proclaimed. He'd suffered it two days earlier, and although the pain had faded, the mark remained from an impact that Huff likened to taking a punch — without consent or preparation. In defiance of his father, Vladimir Guerrero Jr. is swinging significantly less this season. The Pohlads won't sell the Minnesota Twins after all. Milwaukee has run their win streak to 12 games. How much trouble are the New York Yankees and Mets in after their recent struggles? Rookie Cade Horton has brought stability to a depleted Cubs rotation. After not being granted time, White Sox prospect George Wolkow swung the bat with one hand and hit a single. Cubs catcher Miguel Amaya was carted off the field in last night's win. Dodgers right-handed pitcher Brock Stewart is headed to the IL with a shoulder injury. Houston left-handed pitcher Josh Hader is headed to the IL with a shoulder injury. Shohei Ohtani and his agent are facing a lawsuit over allegedly sabotaging a real estate deal in Hawaii. Is it animal abuse to dress up a dog for money outside an MLB ballpark? ($) The NFL is quietly becoming a media juggernaut. As if enough things in your home weren't online already, you can now get a vacuum cleaner with Wi-Fi connectivity. Dale Webster, who surfed daily for over 40 years, passed away at 77. Your song of the day is You Never Know by Immortal Technique:
Yahoo
20 minutes ago
- Yahoo
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company'), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, exemplifying our ability to grow our business as we go from a loss-producing startup to a business that can operate profitably. Following a massive year of positive transformation for Biotricity, we continue to harness the power of workflow automation, AI technology, and other technological enhancements to further improve our operational expenses, margins, and revenues. This powerful combination has set the foundation to fuel ongoing growth. In doing so, we demonstrate our ability to scale with strategic focus and long-term sustainability. The expansion of our Cardiac AI Cloud platform, empowered by strategic partnerships with industry giants, showcases our commitment to revolutionizing medical diagnostics and consumer healthcare. Leveraging over 2 trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months. Strategic alliances forged during fiscal 2025 and 2026 have positioned us to capitalize on expansive market channels, providing access to approximately 90% of all hospitals in America and opening the door to managed care programs, which is a new vertical strategy for Biotricity. These developments mark a significant leap forward in our mission to deliver innovative, accessible, and high-quality cardiac care solutions." Q1-FY26 Financial Highlights Revenue increased 21% to $3.9 million, compared with $3.2 million in Q4 FY24 Gross margin was 80.5% for the three months ended June 30, 2025, as compared to 73.8% in the corresponding prior year quarter; this is the result of expansion in the recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring and cloud cost structure. Net loss decreased to $0.75 million, or $0.03 per share, from a net loss of $6.9 million, or $0.49 per share, in Q1-FY25; this was an 80.6% improvement even after removing the effects of a $3 million one-time deemed dividend in the corresponding prior year period. Positive EBITDA of $333,337, first time in the Company's history; EBITDA increased by 118.7% compared to corresponding prior year quarter; this is the result of growth and operating efficiencies. Operating Highlights for Q1-FY26 and the Future Q1-FY26 recurring (TaaS) Technology Fees rose a robust 11.8% from the corresponding period of the prior year, to $3.4 million, which is also 7.9% increase from the immediately preceding three-month period. Company maintained its track record of strong customer retention, supported by the quality of customer and physician-friendly support services which emphasize the accuracy of our diagnostics and ease-of-use of our solution. Leveraging on its adept development of a range of state-of-the-art products to service a total addressable market of $35 billion. Working on achieving regulatory approval in internation markets, with a view to laying the foundation for distribution in those markets in the coming years, after successfully achieving approvals in Canada, Saudi Arabia and Argentina. Expansion of geographic footprint across 70% of the US, with penetration across thousands of physicians over hundreds of centers, including those acquired through relationships with strategic partners. Secured strategic alliances with three of the top GPOs representing 90% of all hospitals in the US. Full details of the Company's financial results will be filed with the SEC on Form 10-Q and available by visiting Financial Results and Business Update Conference Call Management will host a conference call on Thursday August 14, 2025 at 4:30 p.m. ET to discuss its financial results for fiscal first quarter of 2026 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: Event: Biotricity First Quarter Fiscal 2026 Financial Results and Business Update CallDate: Thursday, August 14, 2025Time: 4:30pm ET (1:30pm PT) Toll Free: 1-877-269-7751 International: 1-201-389-0908 Webcast URL: Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at Toll Free Replay Number: 1-844-512-2921 International: 1-412-317-6671 Replay Access ID: 13755374Expiration: Thursday, August 28, 2025 at 11:59 PM ET About Biotricity Inc. Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit Non-GAAP Measures Non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. It is management's intent to provide non-GAAP financial information to enhance the understanding of Biotricity's GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. Earnings before interest, tax, depreciation and amortization ('EBITDA') is one such measure: 3 months endedJune 30,2025 3 months endedJune 30,2024 $ $ Net loss attributable to common stockholders (754,293 ) (6,948,292 ) Add: Provision for income taxes - - Interest expense 850,254 768,673 Accretion and amortization expenses 153,572 1,144,728 Depreciation 1,488 1,488 Preferred stock dividends 82,316 3,253,772 EBITDA 333,337 (1,779,631 ) Weighted average number of common shares outstanding 26,284,734 14,169,441 Profit (Loss) per Share, Basic and Diluted 0.013 (0.126 ) Important Cautions Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Contacts Investor RelationsBiotricity Investor RelationsInvestors@ SOURCE: Biotricity Inc.
